## Clinical Oversight Review Board (CORB) Criteria for Prescribing/ Criteria-Based Consultation (CBC) Criteria for Coverage

## avacopan (Tavneos)

## Notes:

- Quantity Limits: Yes
- \* Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation

Non-Formulary **avacopan (Tavneos)** requires a clinical review. Appropriateness of therapy will be determined based on the following criteria:

<u>Initiation (new start) criteria</u>: Non-formulary **avacopan (Tavneos)** will be approved for <u>up to 12 months total therapy</u> when the following criteria are met:

- Prescriber is a nephrologist or rheumatologist and patient has a diagnosis of antineutrophil cytoplasmic autoantibody (ANCA)-positive vasculitis, ANCA-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA])
- Patient has a positive test for anti-PR3 or anti-MPO (proteinase 3 or myeloperoxidase antibodies) or positive tissue biopsy
- Patient has a history of significant intolerance to steroids or relative contraindication to steroids OR requires a decrease in cumulative steroid dose due to steroid-induced complications

<u>Criteria for new members entering Kaiser Permanente already taking the</u> <u>medication who have not been reviewed previously</u>: Non-formulary avacopan (Tavneos) will be approved for <u>up to 12 months total therapy</u> when the following criteria are met:

- Prescriber is a nephrologist or rheumatologist and patient has a diagnosis of antineutrophil cytoplasmic autoantibody (ANCA)-positive vasculitis, ANCA-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA])
- Patient has a positive test for anti-PR3 or anti-MPO (proteinase 3 or myeloperoxidase antibodies) or positive tissue biopsy
- Patient has a history of significant intolerance to steroids or relative contraindication to steroids OR requires a decrease in cumulative steroid dose due to steroid-induced complications
- Patient has not been on avacopan for more than 12 months

kp.org

Revised: 08/14/25 Effective: 10/02/25 All plans offered and underwritten by Kaiser Foundation Health Plan of the Northwest

